A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal as a 78-year-old can be”.
Peter Almond finished a trial for donanemab in September having been on the drug for three years.
Donanemab is one of the new “disease modifying” treatments for Alzheimer’s disease, which works by clearing the protein amyloid from the brain.
Mr Almond, who lives in Esher, Surrey, was diagnosed with mild cognitive impairment (MCI) in 2018.
The 78-year-old has taken part in two 18-month trials for donanemab.
Donanemab is given to patients via an intravenous drip once every four weeks.
Mr Almond received his treatment at a trial centre in Guildford, as well as regular MRI and PET scans.
He has not had any side effects.
The Alzheimer’s Research UK fundraiser is worried that his MCI will develop into Alzheimer’s disease now he has finished his course of treatment.
MCI is a condition where memory and thinking problems are mild but noticeable.
Not all cases of MCI lead to dementia but it can be the early stages of diseases such as Alzheimer’s.
“I can’t say for certain that the drug has been slowing down my condition, but I feel that donanemab has helped keep me at the same level as when I started on the trial three years ago,” Mr Almond said.
“I understand the benefits of the drug are modest and that is as much as we can expect from any of these new Alzheimer’s drugs at this point.
“But if it has been stopping my condition developing into Alzheimer’s then it has had a significant impact on my life.
“As of now I feel as normal as a 78-year-old can be. I can read, write, think, plan, walk, drive and even run.
“But I don’t know what will happen in the future.
“Will the amyloid build back up again in my brain now I’m no longer taking the drug?
“The thought of Alzheimer’s disease, of not understanding where I am or what I am doing, is scary to say the least.”
Mr Almond said he is disappointed that the treatment will not be made available on the NHS.
He added: “I understand why Nice (the National Institute for Health and Care Excellence) is unable to accept the drug because of the cost involved.
“But the Government has to pay many millions of pounds to support people in the latter stages of Alzheimer’s disease and the care home sector needs much more income from the state.
“I think it is clear the drug does work to some degree, particularly for people who are or may be in the early stages of Alzheimer’s.”
As well as taking part in a drug trial, Mr Almond has also fundraised to support dementia research.
He completed the London to Brighton Bike Ride in June to raise money for Alzheimer’s Research UK.
He said: “Donanemab and the other new drugs currently in trials are just the start.
“So it’s vital to raise money for research to continue the progress and help the hundreds of thousands of people who are living with dementia.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here